Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) traded up 6.5% on Monday . The company traded as high as $19.93 and last traded at $19.93. 1,177 shares were traded during mid-day trading, a decline of 99% from the average session volume of 79,393 shares. The stock had previously closed at $18.72.
Analysts Set New Price Targets
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an “overweight” rating on the stock.
Get Our Latest Stock Analysis on AAPG
Ascentage Pharma Group International Stock Up 13.0 %
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- What is Insider Trading? What You Can Learn from Insider Trading
- How to Invest in Micro-Cap Stocks Like a Pro
- Investing in the High PE Growth Stocks
- Investors Sell Microsoft Stock on OpenAI News—Time to Buy?
- Election Stocks: How Elections Affect the Stock Market
- Take-Two Interactive: A Defensive Play Set to Explode
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
